This is a research study to find out if Azithromycin or Roflumilast, medicines used in COPD, works better for people with Chronic Obstructive Pulmonary Disease (COPD).

Researchers are looking for current and former smokers with or without COPD to enroll in a registry to be contacted for future studies.

Hypothesis: The development of patient-focused tools and care processes will enable a transition from predominantly office-based CF care to a more convenient, co-produced model. The increased utilization of remote care will be associated with improved adherence to disease monitoring and complication screening guidelines and will increase patient satisfaction. Specific Aims: 1. Customize a patient-facing smartphone application (Nudge) designed to "coach" each patient toward a co-produced goal of convenient and effective health monitoring within the context of enhanced remote care. 2. Develop care processes that facilitate monitoring of respiratory status at home, using home spirometry and remote sputum collection, that include education, electronic reminders, and specimen collection/shipping supplies 3. Implement care processes that allow convenient access to necessary screening procedures, using the Nudge application to provide well-timed electronic reminders and track performance of screening tests.

The purpose of this trial is to allow patients who are currently on the PROSERA trial to receive medication until the study drug is commercially available.

This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progressive phenotype, HRCT images will be collected throughout the study for use in future research efforts.

Evaluate the regional lung function and structural changes using MRI in children with cystic fibrosis (CF) prescribed either immediate or tailored therapy for their pulmonary exacerbation. The primary outcome measure for this ancillary study is the change in ventilation defect percentage (VDP) calculated from Xe MRI, which represents the fraction of the lung with absent or reduced ventilation.

Evaluate the differences between two different treatment durations for exacerbations in a pediatric sample to determine which should be clinical standard.

We are performing a clinical study to determine the optimal frequency for medications for infected pleural fluid, referred to as intrapleural enzyme therapy (IET). Participants will either receive once daily IET or twice daily IET. We hypothesize that once daily IET will be non-inferior to twice daily IET.

We are looking for links between cystic fibrosis outcomes and a history of intimate partner violence.

Gather detailed information on the health and treatment of patients with severe asthma worldwide, track how well patients are responding to treatment, and undertake medical research using data from the registry to improve asthma treatment and care.